[Special Stock] Pharmaresearch Secures 200 Billion Investment... "Boost for Overseas Expansion"

Pharmaresearch is showing strong performance. It is interpreted that the securities firm's analysis, which expects accelerated entry into Europe due to a 200 billion KRW investment attraction, has had an impact.

As of 10:05 AM on the 6th, Pharmaresearch was trading at 182,000 KRW, up 2,200 KRW (1.24%) compared to the previous trading day.

Pharmaresearch announced that it secured an investment of 200 billion KRW through the issuance of Redeemable Convertible Preferred Shares (RCPS) from the European global private equity fund CVC the day before.

Through this investment, Pharmaresearch plans to actively utilize CVC's global network and extensive market experience to expand its overseas business stably and swiftly. In particular, CVC will play a key partner role in Pharmaresearch's global expansion strategy and plans to provide networks and resources in overseas markets together. The company expects to achieve more competitive results in entering new markets and expanding its business through this.

Jung Donghee, a researcher at Samsung Securities, said, "This 200 billion KRW investment attraction is the first step of Pharmaresearch's global expansion strategy established since the first half of this year," adding, "It is expected to shorten the timeline for entering the European market, which was previously set at over five years, to within three years."

He explained, "We will be able to utilize CVC's portfolio, which includes seven dermatology, plastic surgery, and general hospital chains in Europe and Southeast Asia, as well as various sectors such as consumer goods, healthcare, finance, technology, media, and telecommunications," and added, "After Europe, we plan to sequentially enter the US and South American markets."